Keryx Biopharmaceuticals Inc

Keryx Biopharmaceuticals — Q2 2017 Earnings Presentation

16 slides from Keryx Biopharmaceuticals's earnings presentation, Jul 27, 2017

  1. Slide 1: Second Quarter 2017 Financial Results

    Keryx Biopharmaceuticals, Inc. Second Quarter 2017 Financial Results July 27, 2017 Building a Leading Renal Company Exhibit 99.2

  2. Slide 2: Agenda – Second Quarter 2017 Financial Results

    Agenda – Second Quarter 2017 Financial Results Topic Speakers Introduction Amy Sullivan, SVP, Corporate Affairs Business Highlights Greg Madison, President & CEO 2017 Guidance/2Q’17 Results Scott Holmes, SVP & CFO Maximizing Auryxia® Doug Jermasek, VP, Marketing & Strategy Question & Answer All

  3. Slide 3: Forward-looking Statements

    Forward-looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development of Auryxia, our updated 2017 financial guidance and the submission of an sNDA to the FDA to expand the label of ferric citrate to inclu

  4. Slide 4: Recent Business Progress

    Recent Business Progress Greg Madison President and Chief Executive Officer

  5. Slide 5: Recent Business Progress

    Reported ~21,100 prescriptions for 2Q’17, a 61% increase compared to 2Q’16 Increased 2017 net U.S. Auryxia product sales guidance to $62 to $66 million from $56 to $60 million Recent formulary additions at two major Part D providers, which increased access to 95% across Medicare Part D and commercia

  6. Slide 6: Financial Highlights

    Financial Highlights Scott Holmes SVP and Chief Financial Officer

  7. Slide 7: Guidance: 2017 Net U.S. Auryxia Product Sales

    Guidance: 2017 Net U.S. Auryxia Product Sales Increased 2017 Auryxia guidance to $62 to $66 million, from $56 to $60 million, based upon: Strong 2Q prescription level and underlying demand Impact of broad formulary access: 95% of phosphate binder patients with Medicare Part D and commercial insuranc

  8. Slide 8: Strong 2Q 2017 Auryxia Prescription Demand

    Sources: IMS, Davita Rx, Fresenius Rx and Keryx data on file. Strong 2Q 2017 Auryxia Prescription Demand +61% IMS / Specialty mix 2Q 2017: 54% / 46% prescriptions

  9. Slide 9: Selected Second Quarter 2017 Financial Results

    Selected Second Quarter 2017 Financial Results ($ in millions) 2Q 2017 (unaudited) 2Q 2016 (unaudited) Net U.S. Auryxia Product Sales $ 14.1 $ 8.3 License Revenue $ 1.0 $ 1.0 Total Revenue $ 15.1 $ 9.3 Cost of Goods Sold $ 4.4 $ 5.1 Operating Expenses* $ 34.0 $ 27.2 Net loss** $ 86.5 $ 44.7 (In mill

  10. Slide 10: Maximizing Auryxia

    Maximizing Auryxia® Doug Jermasek Vice President, Marketing and Strategy

  11. Slide 11: Strong Performance Driven by Multiple Factors

    Increased breadth and depth of prescribing High level of brand awareness and growing clinical familiarity Increased yield from our prescriber interactions and growth in number of new Auryxia patients Positive clinical experience with Auryxia Early signs of recent Medicare Part D formulary additions

  12. Slide 12: Near-term Focus to Maximize Potential of Auryxia

    Near-term Focus to Maximize Potential of Auryxia Significantly more dialysis patients could benefit from treatment with Auryxia Foundation PDUFA for second indication 11/6/17 Strong momentum in dialysis provides solid foundation for IDA opportunity Meaningful progress with pre-launch preparations La

  13. Slide 13: Maximizing the Potential for Auryxia: IDA Opportunity

    Maximizing the Potential for Auryxia: IDA Opportunity Provides Significant Leverage 95 Renal Sales Specialists Current Physician Targets Care for 450,000 dialysis patients Care for 1.7 million pre-dialysis CKD patients Auryxia Conversations Auryxia Covered on all major Medicare Part D and Commercial

  14. Slide 14: Closing Remarks

    Closing Remarks Greg Madison President and Chief Executive Officer

  15. Slide 15: Key Takeaways

    Key Takeaways Strong second quarter 2017 growth supports $62 to $66 million in full year 2017 net U.S. Auryxia product sales guidance Large unmet need in iron deficiency anemia; preparing for potential launch of Auryxia for second indication, pending approval in November 2017 Second indication would

  16. Slide 16: Second Quarter 2017 Financial Results

    Keryx Biopharmaceuticals, Inc. Second Quarter 2017 Financial Results July 27, 2017 Building a Leading Renal Company

Keryx Biopharmaceuticals — Q2 2017 Earnings Presentation on 6ix